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ScienceDirectBipolar disorder is a serious psychiatric disorder, with a high
heritability and unknown pathogenesis. Recent genome-wide
association studies have identified the first loci, implicating
genes such as CACNA1C and ANK3. The genes highlight
several pathways, notably calcium signalling, as being of
importance. Molecular studies suggest that the risk variants
impact on gene regulation and expression. Preliminary studies
using reprogrammed patient-derived cells report alterations in
the transcriptome and in cellular adhesion and differentiation.
Mouse models show that genes involved in circadian biology,
acting via dopaminergic effects, reproduce aspects of the
bipolar phenotype. These findings together represent
significant advances in identification of the genetic and
molecular basis of bipolar disorder, yet we are still far from an
integrated, evidence-based understanding of its
aetiopathogenesis.
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Introduction
Bipolar disorder (BD) is classically characterised by re-
current episodes of depression and elevated mood (ma-
nia), interspersed with periods of normal mood
(euthymia) [1]. In reality, the clinical picture is more
complex, with mixed mood states, residual cognitive
dysfunction [2] and persistent mood instability during
euthymia [3] often observed. During the mood swings,
features of psychosis (delusions and hallucinations) may
occur. The combination of mood and psychotic symptoms
has contributed to uncertainty as to where BD sits within
psychiatric classifications, and in particular its relationship
to schizophrenia and to other mood disorders. BD affects
1–2% of the population, depending on the criteria used,
and usually begins in adolescence or early adulthood.
Morbidity is high, comorbidity with other psychiatricwww.sciencedirect.com disorders common, and suicide occurs in at least 5%,
contributing to a life expectancy that is reduced by over
a decade. Lithium remains the gold standard for pro-
phylaxis, with anticonvulsants, antipsychotics, and
psychological treatments, also playing a key role in
treatment [4].
BD is highly heritable, with estimates of over 80% from
twin studies [5], yet understanding of its genetic basis,
pathogenesis, and pathophysiology have remained frus-
tratingly elusive, even by the standards of other psychi-
atric disorders. This partly reflects its inherent complexity
and a relative dearth of research, but also difficulties in
modelling the disorder in animals or cells. Fortunately,
progress has recently been made in several domains.
Those pertaining to the genetic and molecular aspects
of BD are reviewed here. See [6] for a complementary
review, focusing on the role of oxidative stress and cellular
damage.
Genomics of bipolar disorder
As with other psychiatric disorders, genome-wide associ-
ation studies (GWAS) of single nucleotide polymor-
phisms (SNPs) indicate that the heritability of BD is
attributable largely to multiple loci of small effect.
Table 1 summarises the current genome-wide significant
loci. See [5,7] for recent reviews of BD genetics. Table 1
also notes the gene(s) implicated at each locus, but it is
worth emphasising that the ‘causal’ gene, and true risk
SNP or haplotype, at each locus remains unknown, hin-
dering the interpretation of the GWAS signals, as is the
case for all psychiatric disorders (see [8] for discussion; see
below for discussion of some of the BD-implicated
genes).
Other studies have begun to investigate genotype–phe-
notype relationships within BD, and between BD and
other disorders. Within BD, genetic loci have been relat-
ed to variables such as presence of psychotic symptoms,
suicidality, and body mass index (e.g. [9]). Some of these
analyses have revealed genome-wide associations, but the
samples are inevitably smaller than for the overall BD-
control comparisons; there is also the problem that de-
tailed phenotyping is often not available. Reflecting the
clinical and familial overlaps between BD and other
psychiatric disorders, cross-disorder analyses have been
carried out. These show substantial sharing of risk
loci between BD and schizophrenia [10], and also signifi-
cant commonalities with major depression, but little with
autism or attention-deficit hyperactivity disorder [10,11].Current Opinion in Neurobiology 2016, 36:1–6
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Table 1
Genome-wide significant loci for bipolar disorder.
Locus Implicated gene(s) and symbol(s)
Genome-wide significant in BD
10q21.2 Ankyrin 3 (ANK3)
12p13.3 Calcium channel, voltage-dependent, L-type,
alpha 1C subunit (CACNA1C)
11q14.1 Teneurin transmembrane protein 4 (TENM4,
formerly known as ODZ4)
19p12 Neurocan (NCAN)
6q25.2 Spectrin repeat containing, nuclear envelope 1
(SYNE1)
3p22.2 Tetratricopeptide repeat and anykrin repeat
containing 1 (TRANK1)
5p15.31 Adenylate cyclase 2 (ADCY2)
6q16.1 MicroRNA 2113 (MIR2113); POU class 3
homeobox 2 (POU3F2; formerly known as OTF7)
10q24.33 Arsenite methyltransferase (AS3MT)
Genome-wide significant in BD + schizophrenia (combined)
2q32.1 Zinc finger protein 804A (ZNF804A)
3p21.1 Inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3);
inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)
16p11.2 Mitogen-activated protein kinase 3 (MAPK3)
Genome-wide significant in BD + unipolar depression (combined)
3p21 Polybromo 1 (PBRM1)
Adapted from [5,7,49].Shedding new genetic light on an old debate, these data
support the view that BD and schizophrenia are on a
continuum, rather than being discrete disorders, as they
have conventionally been classified [12].
Despite the progress, several major limitations and
unknowns deserve mention, beyond the need to identify
unambiguously the affected gene(s) at each locus. First,
the causal genetic variant being tagged by the GWAS
SNPs has not been identified. In the absence of known
coding variants in linkage disequilibrium, the likelihood
is that the risk SNPs alter gene regulation and expression
[13]. There is preliminary evidence for this in terms of
expression quantitative trait loci (eQTLs) [11,14,15]
and for some of the individual genes, as discussed below.
Second, the current BD GWAS signals explain only a
fraction of the heritability. The source of the remainder is
unknown, but likely includes many more independent
loci, as well as gene–gene interactions (epistasis), gene–
environment interactions, and a role for copy number
variants (CNVs), although at present the data suggest that
the latter are less important in BD than in schizophrenia
or autism [12]. Other rare variants may also be involved,
including those encoding calcium channel and GABAA
receptor subunits [16,17].
Bipolar disorder genes and pathways
Two main approaches are being taken to understand the
neurobiological consequences of the genes implicated to
date in BD: bioinformatic identification of gene networksCurrent Opinion in Neurobiology 2016, 36:1–6 and pathways, and empirical studies of the expression and
function of individual genes. The latter studies are also
addressing the molecular basis of the genetic associations.
Pathway analyses using gene ontology and related meth-
ods are being carried out in various ways. A prominent
category, for which there is convergent evidence, is
calcium signalling, particularly voltage-gated calcium
channels, identified in several datasets and using differing
approaches. It is notable that calcium signalling was
already hypothesised to be important in BD and its
treatment [18,19]; it was perhaps less expected that this
enhancement of calcium channel genes applies similarly
to schizophrenia, and also extends to other disorders [11].
A range of other pathways are also highlighted in BD by
studies which have combined GWAS data with gene
expression data; these include hormonal regulation, sec-
ond messenger systems and glutamatergic signalling
[20] as well as histone and immune pathways [21]. Each
of these findings should be seen as provisional and in need
of replication, not least given the inadequacies of gene
ontology categories, and the incomplete information be-
ing fed into the analyses. Nevertheless, they do provide
some of the first steps to a more meaningful integrative
molecular classification and understanding of BD.
Complementing these approaches, the leading BD risk
genes are being investigated individually, with the goal of
understanding the neurobiology of the gene, the molec-
ular basis of the disease association, and the functional
impact of the putative risk variant. Three examples are
given here.
CACNA1C encodes the L-type calcium channel Cav1.2
subunit and is arguably the best supported BD gene,
especially if the various lines of prior evidence for altered
calcium signalling in the disorder are taken into account
[18,19]. In addition to many studies reporting neuroim-
aging, cognitive and neurophysiological correlates of
CACNA1C genotype, molecular studies have sought to
show the proximal effect of the BD-associated SNPs. The
risk haplotype, including the main SNP, rs1006737,
resides within the large (300 kb) third intron, and is hence
non-coding. Any functionality is likely to be via an effect
on expression or splicing of CACNA1C – though, as with
all such genetic associations, other explanations are pos-
sible (e.g. effects on antisense transcripts, non-coding
RNAs, or distant genes [13]. The size and complexity
of the gene (6.5 Mb, with at least 55 exons, and an
unknown repertoire of transcript and protein isoforms)
makes this a daunting task – especially since gene regu-
lation is often different between tissues (as well as cell
types and developmental stages), mandating the use of
post mortem brain tissue as part of this approach [22].
In the first such study, in dorsolateral prefrontal cortex
of over 250 individuals, Bigos et al. [23] showed that
genotype affects CACNA1C mRNA abundance with riskwww.sciencedirect.com
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duced neurons derived from fibroblasts show the same
profile (see below). However, Gershon et al. [16] found
the opposite result in cerebellum, and no genotype
effect in parietal cortex, in separate brain series; these
authors examined a larger range of CACNA1C SNPs, but
had considerably smaller sample sizes, than [23]. Rous-
sos et al. [15] also provide some evidence that the risk
allele is associated with reduced CACNA1C expression in
brain tissue, and in cell lines, and reveal a more complex
relationship between CACNA1C gene structure and reg-
ulation beyond that conferred by rs1006737. Further
studies are clearly required, taking into account the
possibility of temporal and spatial specificity of effects,
and genetic influences on splicing of the gene — to date
only the overall CACNA1C transcript abundance has
been assayed.
ANK3 encodes ankyrin G, a scaffold protein involved in
many cellular processes [24]. Like CACNA1C, ANK3 is a
large and complex gene (700 kb, with at least 44 exons
and multiple protein isoforms). With regard to BD, per-
haps the best known feature of ANK3 is that it is located in
the axon initial segment and at nodes of Ranvier, wherein
it couples voltage-gated sodium channels to the cytoskel-
eton [25]. However, a recent study shows that ANK3 is
dispensable for this function [26], whilst Chang et al. [27]
show that ANK3 is expressed by oligodendrocytes, with
anykyrin G abundant on the glial rather than axonal side
of the nodes. These unexpected findings are complemen-
ted by reports showing that ankyrin G may have impor-
tant additional localisations and functions. For example,
Durak et al. [28] show that ANK3 regulates the b-catenin/
Wnt signalling pathway, already implicated in BD. Smith
et al. [29] identified a novel short ANK3 isoform which is
located in dendritic spines and regulates NMDA recep-
tor-dependent plasticity. Interestingly, ANK3 becomes
enriched in this sub-synaptic fraction after chronic lithi-
um treatment [30]. In BD, ANK3 mRNA is increased in
blood [31], but its expression has not been reported in
brain in the disorder. The likelihood of isoform-selective
functions of ANK3 is complemented by preliminary evi-
dence for differential expression of ANK3 isoforms in
human brain and their regulation by BD associated SNPs
[32,33]. The latter study [33] suggests that the risk allele
at rs9804190 is associated with decreased ANK3 mRNA,
but other ANK3 SNPs did not show significant effects on
expression.
ZNF04A (zinc finger protein 804A) was originally identi-
fied as a schizophrenia risk gene but then found to be
associated with a broader psychosis phenotype including
BD. It is thought to encode a transcription factor, and
regulates expression of various genes in vitro [34]. The
best-established psychosis risk allele (rs1344706), located
in the third intron, influences ZNF804A mRNA in foetal
but not adult human brain [35], with the risk allele beingwww.sciencedirect.com associated with lower expression. Tao et al. [36] repli-
cated this observation in prefrontal cortex of a separate,
large sample (n = 697) and showed that genotype impacts
not on the full-length transcript, but on a newly identified,
shorter ZNF804A mRNA isoform. The effect was again
limited to foetal brain, although they also found a geno-
type-by-diagnosis interaction in their BD sample, with
lower expression in patients homozygous for the risk
allele. Complicating interpretation of the data, translation
of the protein encoded by the short ZNF804A transcript
has not been unambiguously demonstrated in human
brain; moreover, its predicted sequence lacks the zinc
finger domain of ZNF804A, and hence nothing is known
about its potential function nor how it may be involved in
BD pathogenesis.
In summary, these examples illustrate the depth and
breadth of research which will be needed to move from
statistical association of BD with a genomic locus to (a)
identifying the affected gene(s), (b) clarifying its role in
the pathogenesis of BD, and (c) determining the patho-
physiological consequences of the risk SNP or haplotype.
Animal models of bipolar disorder
All animal models of psychiatric disorders have inherent
limitations, but BD has suffered particularly from the lack
of a model which recapitulates its core feature,
viz. spontaneous oscillations between manic-, euthy-
mic-, and depressive-like phenotypes. However, there
are several genetic mouse models which show manic-like
behaviour and which have been used to explore its
molecular and neural basis.
SHANK3 point mutations and deletions are linked with
autism, but not with BD. However, Shank3-overexpres-
sing mice show manic-like behaviour, altered circadian
rhythms, and a synaptic excitation/inhibition imbalance,
via a pathway involving the Arp2/3 pathway and increases
in F-actin [37]. Their behavioural phenotype could be
normalised by one commonly used mood stabiliser, sodi-
um valproate, but not by lithium.
The Clock D19 mouse has a mutation in the Clock gene, a
core regulator of the circadian system. The mouse was
noted several years ago to have a diurnal manic-like
behaviour, being hyperactive and with more reward-re-
lated and reduced depressive and anxiety behaviours
during the light phase, but normal behaviour at night
[38]. This manic-like daytime profile coincides with
increased firing of dopamine neurons in the ventral teg-
mental area. Sidor et al. [39], using a novel chronic
optogenetic stimulation paradigm, provide convincing
evidence that enhanced dopaminergic activity is causally
related to the behaviour. They also show that the mech-
anism likely involves Clock acting as a transcriptional
repressor of tyrosine hydroxylase, a gene involved in
dopamine synthesis, suggesting that the Clock D19 mutantCurrent Opinion in Neurobiology 2016, 36:1–6
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mouse model has recently been reported which also
involves a circadian gene (the nuclear receptor REV-
ERBa) regulating dopamine regulation via tyrosine hy-
droxylase repression, and with similar mood-related be-
haviour [40]. These two studies together argue for a
renewed focus on circadian biology, and dopamine, in the
core pathophysiology — and perhaps treatment — of BD
and related psychiatric disorders.
The Shank3 transgenic, Clock D19 and REV-ERBa mice
illustrate how genetic models can be used to identify
synaptic, cellular and synaptic mechanisms underlying
BD-relevant phenotypes. Animal models are also being
used to investigate the function of BD-associated genes.
For example, Leuiss et al. [41] studied ANK3 using
heterozygous Ank3+/ mice, and RNA interference to
knock down Ank3 in the dentate gyrus. Both manipula-
tions led to decreased anxiety and increased motivation
for reward, which were ameliorated by chronic lithium
administration. Moreover the Ank3+/ mice were more
susceptible to depression-like behaviours after chronic
stress, and had higher corticosterone levels, suggestive of
enhanced stress reactivity.
Modelling bipolar disorder in reprogrammed
cells
Notwithstanding these developments, the lack of estab-
lished animal models of bipolar disorder has encouraged
the early adoption of induced pluripotent stem cell
(iPSC) research into the field.
Chen et al. [42] generated iPSCs from fibroblasts of three
BD patients and three controls, and differentiated them
into cells with a forebrain neuronal phenotype. They
reported alterations in the transcriptome of the BD-de-
rived neurons (but not the iPSCs), including up-regulation
of some receptor and ion channel transcripts and those
specifying a ventral rather than dorsal telencephalic fate.
Wang et al. [43] took a different technical approach,
directly trans-differentiating fibroblasts to neuron-like
cells (induced neurons), from 12 BD patients (6 lithium
responders, 6 non-responders) and 6 healthy controls.
Using a label-free optical imaging method, they measured
parameters related to cell growth, size, and adhesion. The
main finding was that lithium responsive patients’ neu-
rons showed greater adhesion compared to those of lithi-
um non-responders. Cells from control subjects were
intermediate between these two groups, and the BD
group overall did not show differences from the controls.
The study highlights that research using iPSCs, and
derived neuronal-related cells may have value for under-
standing drug actions as well as disease pathophysiology.
Madison et al. [44] used a family-based paradigm, gener-
ating iPSC lines and then neural progenitor cells from twoCurrent Opinion in Neurobiology 2016, 36:1–6 brothers with BD and their two unaffected parents. No
differences were seen for the iPSCs between affected and
unaffected members, but the neural progenitors showed
several differences, including alterations in neurogenesis
and in the expression of neuroplasticity-related genes
including Wnt and ion channels.
Another experimental design is to compare cells derived
from subjects on the basis of genotype, rather than by
diagnosis, to examine genetic mechanisms. Yoshimizu
et al. [45] took fibroblasts to make induced neurons
from 24 subjects genotyped for rs1006737, the risk-asso-
ciated SNP in CACNA1C, and examined the expression
and function of calcium channels. They found elevated
CACNA1C mRNA, and greater calcium current density, in
the neurons derived from risk homozygotes compared to
heteroyzgotes and non-risk homozygotes. These data
support the view that the risk variants of CACNA1C
may involve a gain rather than a loss of function, and
strengthen the rationale for L-type calcium channel
antagonists as potential therapeutic agents in BD.
In summary, studies using reprogrammed cells are pro-
viding intriguing clues about the pathophysiology of
neuronal-like cells derived from patients with BD, or
related to its genetic risk. However, no clear pattern or
convergence of findings has yet emerged, and much
remains to be done in terms of detailed phenotyping,
and particularly in the scaling up of experiments to
provide robust and generalisable results.
Conclusions
Recent findings have made inroads into revealing the
genetic and molecular basis of BD, and have provided
support for the long-suspected (but still poorly charac-
terised) role of calcium signalling in the disorder, as well
as implicating pathways and processes which were less
anticipated. There is a long road ahead in terms of
identifying the pathophysiological implications of the
risk genes, and understanding how their functioning is
impacted by the risk variants. At present, the effects
appear to be mediated through altered gene expression
and thence function, with some evidence that specific
isoforms in each gene may be important. The challenges
and opportunities ahead are both empirical and bioinfor-
matic, and both will expand substantially with the forth-
coming GWAS from the Psychiatric Genomics
Consortium involving 20,000 BD cases and 28,000 con-
trols [7] which will no doubt reveal many more loci. In
tandem with the ongoing efforts to understand the mo-
lecular mechanism of action of lithium and other mood
stabilisers [46–48], there are grounds for cautious opti-
mism that transformative advances in therapies for BD
will soon be possible. These are long overdue.
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